A PHASE III, MULTICENTER, RANDOMIZED,PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE-NEGATIVE BREAST CANCER
This study is being conducted to determine the efficacy and safety in using Atezolizumab (MPDL3280A) in combination with nab-paclitaxel in treating patients with metastatic breast cancer. The safety of single-agent nab-paclitaxel has been determined in previous studies of patients with metastatic breast cancer, and preliminary data shows the use of Atezolizumab (MPDL3280A) is safe to use in combination with chemotherapy.
* Metastatic or locally advanced, histologically documented Triple-Negative Breast Cancer (TNBC)
* No prior chemotherapy or targeted systemic therapy for inoperable locally advanced or metastatic TNBC
Alison Conlin, M.D.
- Oncology and Hematology Care Eastside